Recent news highlights IRIDEX’s narrowing net loss in Q4 2025 driven by retina sales growth, ongoing earnings calls, and strategic investments.

• IRIDEX reported a narrowed Q4 loss year over year, supported by growth in retina system sales and glaucoma probe sales [N1].
• The company held its Q4 2025 earnings call discussing financial results and operational updates [N3].
• Zacks initiated coverage of IRIDEX with a neutral recommendation in early 2026 [N4].
• IRIDEX reported a 7% revenue gain in Q2 2025, reflecting ongoing sales momentum [N5].
• An insider purchase of 20,000 shares by a director was reported in mid-2025 [N6].
• The company closed a $10 million strategic investment with Novel Inspiration International Co., Ltd. in March 2025 [N8].

IRIDEX’s proprietary laser technologies offer clinically effective and safer treatment options for glaucoma and retinal diseases, which have been adopted globally by ophthalmologists. The company’s recurring revenue model from consumables and service contracts supports stable revenue streams. Recent revenue growth driven by retina system and glaucoma probe sales, along with cost reductions leading to narrower net losses, demonstrate operational improvements. The 2024 Local Coverage Determination clarifying reimbursement limitations on competing MIGS procedures may increase physician interest in IRIDEX’s laser treatments, potentially enhancing market opportunities.

IRIDEX faces risks from regulatory approval delays or failures that could materially impact its business. The company’s financial performance is affected by macroeconomic uncertainties, including capital expenditure constraints in healthcare settings, tariffs, and geopolitical risks. Customer concentration, with one customer accounting for a significant portion of revenues and receivables, poses revenue risk. Gross margin pressure from inventory write-downs and increased product costs, along with ongoing net losses and accumulated deficit, highlight financial challenges. Currency fluctuations impact international sales denominated in Euros. The company’s ability to sustain liquidity and manage operating losses remains a concern.

IRIDEX’s moat is based on its proprietary MicroPulse® and Endpoint Management™ laser technologies, which provide safer, tissue-sparing treatment options for glaucoma and retinal diseases compared to standard continuous-wave laser therapies. The company’s specialized product lines and consumable probes create recurring revenue streams and customer dependency. Its direct sales presence in key markets like the US and Germany, combined with distributor networks internationally, supports market penetration. Regulatory approvals and clinical adoption of its technologies contribute to competitive differentiation. However, the moat is challenged by reliance on a limited number of suppliers, customer concentration, and evolving reimbursement landscapes.

• Regulatory Approval Risks: Delays or failures in obtaining FDA or international regulatory approvals for products could materially affect business operations and financial results.
• Customer Concentration: One customer, Topcon, accounted for approximately 32% of revenues and 20% of receivables in fiscal 2025, creating dependency risk.
• Macroeconomic and Geopolitical Risks: Recession fears, tariffs, inflation, and geopolitical uncertainties have impacted capital equipment purchasing demand and may continue to affect sales cycles and profitability.
• Currency Fluctuation Risks: Sales through the German office are denominated in Euros and subject to currency exchange risks, which could affect revenue and profitability.
• Financial Performance and Liquidity: The company has incurred net losses and has an accumulated deficit of approximately $92.4 million, with ongoing cash burn requiring careful liquidity management.

• IRIDEX is an ophthalmic medical technology company focused on developing and commercializing products and procedures to treat sight-threatening eye conditions including glaucoma and retinal diseases.
• The company’s proprietary MicroPulse® Technology and Endpoint Management™ Technology are used for treatment of glaucoma and retina disorders, offering low-energy, tissue-sparing laser therapy as alternatives to standard continuous-wave laser treatment.
• Product lines include laser consoles for glaucoma (Cyclo G6®), medical retina (IQ 532®, IQ 577®, PASCAL System), and surgical retina (OcuLight® TX and SLx).
• Recurring revenues are generated from sales of consumable single-use laser probe devices, repair, service, and extended service contracts.
• Sales are primarily direct in the US and Germany, and through independent distributors internationally (excluding Germany).
• Total revenues were $52.7 million in fiscal year 2025, up 8.2% from $48.7 million in 2024, driven by higher retina system sales, glaucoma probe sales, and an extra selling week in 2025.
• Net loss narrowed to $4.4 million in fiscal 2025 from $8.9 million in 2024.
• Gross margin decreased from 40.1% in 2024 to 36.5% in 2025 due to inventory write-downs, increased product costs from tariffs, and lower capitalization of manufacturing overhead.
• Operating expenses decreased significantly in 2025 compared to 2024, with research and development down 32.7%, sales and marketing down 17.4%, and general and administrative down 20.9%, reflecting cost savings and workforce reductions.
• The company had cash and cash equivalents of $6.0 million and working capital of $12.0 million as of January 3, 2026, with a current ratio of 1.91 and cash ratio of 0.46.
• Net cash used in operating activities was $2.1 million in 2025, improved from $7.3 million in 2024, mainly due to reduced net loss and inventory levels.
• Financing activities in 2025 provided $6.0 million, primarily from issuance of Series B preferred stock and a convertible note payable to Novel Inspiration International Co., Ltd.
• IRIDEX’s common stock is listed on Nasdaq Capital Market under ticker IRIX, with approximately 32 holders of record as of March 31, 2026.
• The company has never paid cash dividends and intends to retain earnings for business use.
• IRIDEX leases facilities in Mountain View, California (headquarters) and internationally in Germany and the Philippines.
• The company’s products require FDA and international regulatory approvals; delays or failures in approvals could materially impact business.
• Sales to international distributors are denominated in U.S. dollars, mitigating currency risk, but sales through the German office are denominated in Euros and subject to currency fluctuation risks.
• One customer, Topcon, accounted for approximately 32% of total revenues in fiscal 2025 and 35% in 2024, and represented 20% of receivables as of January 3, 2026.
• The company’s manufacturing strategy includes continuous process development, with some outsourcing and insourcing to optimize supply continuity, quality, and margins.
• The company offers a standard two-year warranty on system sales and optional service contracts sold in incremental one-year periods after warranty expiration.
• The company’s laser therapies have been adopted globally by ophthalmologists for managing glaucoma and retinal diseases.
• Macroeconomic conditions such as recession fears, tariffs, inflation, and geopolitical uncertainties have impacted capital equipment purchasing demand and timing, leading to extended customer purchase decision cycles.
• Local Coverage Determination (LCD) L37531 adopted in 2024 affects Micro-Invasive Glaucoma Surgery reimbursement but does not affect IRIDEX’s Cyclo G6® product family, potentially increasing physician interest in IRIDEX’s laser treatments.
• The company’s effective tax rate was -1.3% for fiscal 2025, with a valuation allowance of $27.5 million at year-end.
• The company’s accumulated deficit was approximately $92.4 million as of January 3, 2026.